Verifying Antibodies After Live Immunization Delivery (VALID): a Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

Children's Hospital Medical Center, Cincinnati0 个研究点目标入组 130 人开始时间: 2025年3月13日最近更新: 2026年1月21日

试验速览

阶段: 不适用
状态: 招募中
发起方: Children's Hospital Medical Center, Cincinnati
入组人数: 130

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

详细描述

Families of infants with SCD who are eligible for a measles vaccine per standard care will be contacted to discuss enrollment in the study. One cohort will be evaluated for response to the first measles vaccine (MV1) and another cohort will be evaluated for response to the second measles vaccine (MV2). Blood samples will be collected from participants prior to measles vaccination and then again at 4 and 8 weeks after vaccination.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

年龄范围: 6 Months 至 6 Years（Child）
性别: All
接受健康志愿者: 否

入选标准

•Participants with confirmed Sickle Cell Disease.
•Participants 6 months and 6 years of age and due for measles vaccination within 3 months per national guidelines.
•Willing and able to provide informed consent
•Ability to comply with study related evaluations and follow-up visits.

排除标准

•1. Known primary immunodeficiency syndrome, cancer, or acquired immunodeficiency syndrome (AIDS) that would preclude vaccination with live virus vaccines.

研究者

发起方

Children's Hospital Medical Center, Cincinnati

申办方类型

Other

责任方

Sponsor

相似试验

进行中（未招募）

1 期

A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.

NCT07280858SK Bioscience Co., Ltd.368

招募中

1 期

Study of IADADEMSTAT for the Treatment of Sickle Cell Disease.Sickle Cell Disease

2025-521838-29-00Oryzon Genomics S.A.30

招募中

2 期

Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma

2024-515295-12-00Antwerp University Hospital10

招募中

2 期

Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease EndotypeSickle Cell DiseaseSickle Cell Anemia

NCT07282210Biossil Inc.105

招募中

不适用

Immune Profiling of Refractory cSLE Exposed to CD3×CD19 BiTE

NCT07352332The Children's Hospital of Zhejiang University School of Medicine6